Chinese University of Hong Kong
The test relies on a spermine risk score coupled with a urine test to predict which patients are most likely to have prostate cancer.
Prenetics, Prudential, CUHK, Others Partner to Increase COVID-19 Test Access in Hong Kong
The Project Screen initiative aims to provide the Hong Kong community with home access to the World Health Organization-approved RT-PCR test for SARS-CoV-2 at zero profit to its organizers.
Hong Kong's Take2 to Commercialize Early Cancer Detection Test; Focus on Healthcare Informatics
Premium
Take2 Health plans to launch an nasopharyngeal carcinoma early detection test in the next several months in Hong Kong and southern China.
Hong Kong Startup Licenses Nasopharyngeal Cancer Early Detection Technology From Grail
Take2 was founded by Chinese University of Hong Kong researchers and will commercialize a cell-free DNA test for early cancer detection.
Team Describes Early Detection Test for Nasopharyngeal Carcinoma; Grail to Commercialize This Year
Premium
The NGS-based test improves on a previous PCR-based version and detects circulating DNA from Epstein Barr virus that is shed from cancer cells.
Dec 14, 2016